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Higher plasma levels of complement C3a,
C4a and C5a increase the risk of subretinal
fibrosis in neovascular age-related macular
degeneration
Complement activation in AMD
Judith Lechner, Mei Chen, Ruth E. Hogg, Levente Toth, Giuliana Silvestri, Usha Chakravarthy
and Heping Xu*
Abstract
Background: The aim of this study was to investigate the plasma levels of complement C3a, C4a, and C5a in
different types of neovascular age-related macular degeneration (nAMD) and whether the levels were related
to patients’ responsiveness to anti-VEGF therapy.
Results: Ninety-six nAMD patients (including 61 with choroidal neovascularisation (CNV), 17 with retinal angiomatous
proliferation (RAP), 14 with polypoidal choroidal vasculopathy (PCV) and 4 unclassified patients) and 43 controls were
recruited to this case–control study. Subretinal fibrosis was observed in 45 nAMD patients and was absent in 51 nAMD
patients. In addition, the responsiveness to anti-VEGF (Lucentis) therapy was also evaluated in nAMD patients.
Forty-four patients were complete responders, 48 were partially responders, and only 4 patients did not respond to the
therapy. The plasma levels of C3a, C4a and C5a were significantly higher in nAMD patients compared to
controls. Further analysis of nAMD subgroups showed that the levels of C3a, C4a and C5a were significantly
increased in patients with CNV but not RAP and PCV. Significantly increased levels of C3a, C4a and C5a were
also observed in nAMD patients with subretinal fibrosis but not in those without subretinal fibrosis. Higher
levels of C3a were observed in nAMD patients who responded partially to anti-VEGF therapy.
Conclusions: Our results suggest increased systemic complement activation in nAMD patients with CNV but
not RAP and PCV. Our results also suggest that higher levels of systemic complement activation may increase
the risk of subretinal fibrosis in nAMD patients.
Keywords: Age-related macular degeneration, Choroidal neovascularisation, Complement, Subretinal fibrosis
Background
Neovascular age-related macular degeneration (nAMD),
or wet AMD, is the leading cause of blindness in the eld-
erly population and is characterised by the growth of ab-
normal blood vessels in the macular region of the retina.
There are different subtypes of nAMD and the most
commonly encountered is choroidal neovascularisation
(CNV) which is characterised by the infiltration of
abnormal neovascular complexes into the space between
the retinal pigment epithelium and Bruch’s membrane
or the subretinal space [1]. Neovascular complexes may
also arise de novo from retinal vasculature known as
retinal angiomatous proliferation (RAP) and these are
known to fuse with CNV [2]. Another subtype of
neovascularisation, polypoidal choroidal vasculopathy
(PCV), is characterised by a branching vascular network
arising from the choroid with polypoidal lesions under-
neath the RPE [3]. VEGF is elevated in eyes of nAMD
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patients and plays an important role in the neovasculari-
sation process and vascular permeability in nAMD and
intravitreal injection of anti-VEGF antibody is the stand-
ard care for nAMD [1].
The pathogenesis of AMD is complex and incom-
pletely understood with genetic as well as clinical and
environmental factors (such as age, family history of
AMD, cardiovascular disease, body mass index and
cigarette smoking) known to influence the risk of de-
veloping this disease, however, the underlying mecha-
nisms remain elusive [4–6]. Compelling evidence
suggests that inflammation plays a critical role in the
aetiology of AMD [7, 8] and a number of studies
have specifically highlighted the role of the comple-
ment system in AMD. Many of the genetic variants
that have been associated with AMD lie in genes in-
volved in the complement cascade, including comple-
ment factor H (CFH) [9], complement component 3
(C3) [10], complement component 2 (C2) and com-
plement factor B (CFB) [11]. A number of studies
have shown increased levels of complement expres-
sion in the maculae of AMD patients [12, 13]. Com-
plement fragments, including C3a and C5a [14], and
the membrane attach complex (MAC or C5b-9) [15]
were found in drusen of patients with AMD as well
as complement activating proteins such as amyloid
beta [16] and lipofuscin [17]. Besides the local com-
plement activation in AMD, systemic complement ac-
tivation has also been detected in patients with AMD.
Increased serum levels of complement fragments (e.g. Ba,
C3d) [18–20] and changes in the expression of comple-
ment regulatory proteins (e.g. CD46, CD59) [21] have
been reported in AMD. Complement activation and accu-
mulation of MAC has been found in choriocapillaris,
which are part of the systemic circulation, during normal
aging and especially in patients with AMD [22]. It is clear
that uncontrolled or dysregulated complement activation
may contribute to macular lesion development in AMD,
which offers the opportunities for complement-targeted
immune therapy. Indeed a number of complement inhibi-
tors are in phase I, II and III clinical trials for AMD [23,
24]. In view of the diversity of AMD phenotype, it is likely
that different immune mechanisms may be involved in
different types of AMD, and this is exemplified by the di-
verse response to anti-VEGF therapy observed in various
clinical studies [25]. Therefore, it is important to under-
stand which type(s) of AMD is associated with uncon-
trolled complement activation.
The complement system can be activated through the
classical pathway (CP), the mannose-binding lectin
(MBL) pathway and the alternative pathway (AP) [26].
Complement fragments C3a and C5a can be generated
by any of these activation pathways, whereas C4a is gen-
erated when the CP or MBL pathway is activated.
Elevated levels of these complement fragments are indic-
atives of increased complement activation. In this study,
we measured the plasma levels of C3a, C4a and C5a in
nAMD patients and correlated the expression levels with
clinical presentations as well as the responsiveness to
anti-VEGF therapy. Ninety-six nAMD patients (in-
cluding 61 CNV, 17 RAP, 14 PCV and 4 unclassified
patients) and 43 controls were recruited to this case–
control study.
Results
Clinical evaluation
Of the 139 study participants, 43 were controls and 96
had diagnosed nAMD. Despite our efforts to recruit age
matched controls, there was a significant difference in
age between controls and nAMD patients (P = 0.002)
as shown in Table 1. There were no significant differ-
ences regarding gender distribution, family history of
AMD, history of cardiovascular disease, history of
hypertension, history of diabetes, BMI and smoking
habits between controls and nAMD patients. There
were more patients taking vitamins and low-dose as-
pirin compared to controls (P = 0.011 and 0.001 re-
spectively) (Table 1).
The average duration between the last anti-VEGF
treatment and the day of blood collection was 140.1 ±
223.8 days (interquartile range: 42.0–127.0 days). No
participant had received anti-VEGF treatment within
4 weeks prior to blood collection. The average number
of anti-VEGF injections received per nAMD patient
prior to blood collection was 16.1 ± 10.7 (interquartile
range 8.3–21.8). There was no correlation between the
number of anti-VEGF injections received and the
concentration of C3a (Pearson's correlation coefficient
(r) = 0.08; P = 0.448), C4a (r = −0.03; P = 0.771) and
C5a (r = −0.16; P =0.131) (see Additional file 1).
Complement fragments in nAMD patients and controls
All three complement fragments, C3a, C4a and C5a
were significantly increased in nAMD patients compared
to controls in the univariate analysis (P < 0.001, P = 0.005
and 0.049 respectively) and these associations remained
significant in the multivariate analysis after correction
for age and gender (P = 0.001, 0.012 and 0.045 re-
spectively) (Table 2). In the nAMD group, C3a and
C4a were significantly increased in those with a fam-
ily history of AMD (P = 0.058 and 0.011 respectively)
compared to those without a family history of AMD.
The plasma level of C5a was not associated with a
family history of AMD. Due to this association, we
included the confounder “family history of AMD” in
the multivariate analysis.
When comparing nAMD patients and controls, after
including the confounder “family history of AMD” in
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the multivariate analysis for C3a and C4a, the increase
in C3a and C4a in the nAMD group remained signifi-
cant (P = 0.005 and 0.031 respectively) as shown in
Table 2. The concentrations of complement components
were not associated with vitamin or low dose aspirin in-
take or any other confounders.
Complement fragments in patients with CNV, RAP and
PCV
Out of the 96 nAMD participants, 61 had CNV, 17
with RAP, 14 with PCV and 4 were unknown. There
were no significant differences in complement compo-
nents when comparing between neovascular AMD
subtypes, although there was a trend for higher C3a,
C4a and C5a concentrations in those classified as
CNV. On comparing subgroups of nAMD participants
with controls, there was a significant increase in C3a,
C4a and C5a in those with CNV when compared to
controls in the univariate analysis (P < 0.001, P = 0.003
and 0.044 respectively; Table 3) and these associations
remained significant in the multivariate analysis after
correction for age and gender as well as family his-
tory of AMD for C3a and C4a (P = 0.001, 0.009 and
0.008 respectively). There were no significant differ-
ences in the plasma levels of C3a, C4a, and C5a be-
tween RAP or PCV versus controls (Table 3).
Complement fragments and subretinal fibrosis
Subretinal fibrosis was present in 45 (47 %) of nAMD pa-
tients (Table 4). When comparing complement fragments
in patients with and without fibrosis to controls, C3a was
significantly increased in both groups compared to the
Table 2 C3a, C4a and C5a plasma levels in nAMD patients and controls
Univariate
analysis
Multivariate analysis (age and gender) Multivariate analysis (age, gender
and family history of AMD)
Variables (ng/ml) Controls
(mean ± SD)
n = 43
nAMD
(mean ± SD)
n = 96
P value
nAMD vs
Controlsa
P value
nAMD vs
Controlsb
Odds ratio 95 % confidence
interval for odds
ratio
P value
nAMD vs
Controlsc
Odds ratio 95 % confidence
interval for odds
ratio
C3a 11.95 ± 3.30 14.65 ± 4.48 <0.001 0.001 241.44 8.44–6910.14 0.005 140.67 4.53–4372.57
C4a 68.91 ± 33.23 108.48 ± 83.83 0.005 0.012 5.81 1.46–23.05 0.031 4.79 1.15–19.88
C5a 8.34 ± 2.05 9.43 ± 2.73 0.049 0.045 20.55 1.07–396.06
aIndependent samples t-test
bMultinomial logistic regression corrected for age and gender
cMultinomial logistic regression corrected for age, gender and family history of AMD
Bold P < 0.05
SD standard deviation
Table 1 Demographic and clinical characteristics of nAMD patients and controls
All Controls nAMD P value
(n = 139) (n = 43) (n = 96) nAMD vs Control
Age (median (range)), years 78.6 (53–93) 74.0 (58–92) 80.1 (53–93) 0.002a
Female (number (%)) 63 (45) 19 (44) 44 (46) 1.000b
Family history of AMD (number (%)) 32 (23) 6 (14) 26 (27) 0.127b
History of cardiovascular disease (number (%)) 36 (26) 9 (21) 27 (28) 0.528b
History of hypertension (number (%)) 81 (58) 23 (53) 58 (60) 0.576b
History of diabetes (number (%)) 15 (11) 2 (5) 13 (14) 0.150b
Body Mass Index (mean ± SD) 26.1 ± 4.4 26.1 ± 5.1 26.0 ± 4.0 0.980c
Smoking status 0.381b
Non-smoker (number (%)) 56 (40) 20 (47) 36 (38)
Former smoker (number (%)) 70 (50) 20 (47) 50 (52)
Current smoker (number (%)) 12 (9) 2 (5) 10 (10)
Taking cardiovascular medication (number (%)) 102 (73) 28 (65) 74 (77) 0.212b
Taking vitamins (number (%)) 28 (20) 3 (7) 25 (26) 0.011b
Taking low-dose aspirin (number (%)) 43 (31) 5 (12) 38 (40) 0.001b
aMann Whitney U test
bPearson’s chi-square test
cIndependent samples t-test
SD standard deviation
Bold P < 0.05
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controls in the univariate analysis (P = 0.046 and
<0.001 respectively; Table 4). After adjustment for
age, gender and family history of AMD the difference
in C3a between controls and patients with fibrosis
remained highly significant (P = 0.001), whereas the
difference between controls and patients without fi-
brosis was insignificant (P = 0.055). C4a was signifi-
cantly increased in participants with fibrosis when
compared to controls in the univariate (P = 0.003;
Table 4) and multivariate analysis (P = 0.010). For
C5a, the univariate analysis did not detect any signifi-
cant differences between participants with or without
fibrosis when compared to controls, however in the
multivariate analysis there was a significant difference
in C5a when comparing participants with fibrosis to
controls (P = 0.018).
Complement fragments and responsiveness to
anti-VEGF therapy
Of the 96 nAMD patients, 44 (46 %) responded com-
pletely to the anti-VEGF therapy, 48 (50 %) partially
responded to the therapy and 4 patients (4 %) did not
respond to the therapy. Due to the limited number of
non-responders in this study, this group was not in-
cluded in the statistical analysis. When comparing the
concentration of plasma complement fragments be-
tween partial and complete responders, we found a
significant increase in C3a in partial responders in
the univariate analysis (P = 0.041; Table 5) and the
difference remained significant in the multivariate
analysis after correcting for age, gender and family
history of AMD (P = 0.033). No significant differences
in plasma levels of C4a and C5a were identified when
Table 3 Univariate analysis of C3a, C4a and C5a plasma levels in nAMD patients with CNV, RAP and PCV
Variables
(ng/ml)
Controls
(mean ± SD)
CNV
(mean ± SD)
RAP
(mean ± SD)
PCV
(mean ± SD)
P value controls
vs CNV vs RAP vs PCVa
P value
Bonferroni
post hoc testn = 43 n = 61 n = 17 n = 14
C3a 11.95 ± 3.30 15.29 ± 4.29 14.15 ± 5.93 12.55 ± 2.86 <0.001 <0.001b
0.609c
1.000d
C4a 68.91 ± 33.23 118.16 ± 93.41 84.73 ± 55.07 96.51 ± 63.71 0.004 0.003b
1.000c
1.000d
C5a 8.34 ± 2.05 9.92 ± 2.81 8.10 ± 2.53 8.68 ± 1.95 0.016 0.044b
1.000c
1.000d
aOne-way ANOVA
bControls vs CNV
cControls vs RAP
dControls vs PCV
Bold P < 0.05
SD standard deviation
Table 4 Univariate analysis of C3a, C4a and C5a plasma levels in participants with nAMD with and without subretinal fibrosis
Variables
(ng/ml)
Controls
(mean ± SD)
Fibrosis absent
(mean ± SD)
Fibrosis present
(mean ± SD)
P value P value P value
n = 43 n = 51 n = 45 Fibrosis absent vs
presenta
Fibrosis absent vs
present vs controlsb
Bonferroni post
hoc test
C3a 11.95 ± 3.30 13.68 ± 3.05 15.75 ± 5.51 0.051 <0.001 0.046c
<0.001d
C4a 68.91 ± 33.23 93.95 ± 59.44 124.94 ± 103.14 0.102 0.004 0.258c
0.003d
C5a 8.34 ± 2.05 9.14 ± 2.66 9.75 ± 2.80 0.343 0.088
aIndependent samples t-test
bOne-way ANOVA
cControls vs Fibrosis absent
dControls vs fibrosis present
Bold P < 0.05
SD standard deviation
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comparing complete responders with partial responders
as shown in Table 5. The response to anti-VEGF therapy
was not associated with the presence of subretinal fibrosis
(P = 0.682; Pearson’s chi-square test).
Discussion
In the present study we report that complement frag-
ments C3a, C4a and C5a are significantly elevated in the
plasma of nAMD patients when compared to controls.
Hence our results confirm previous findings of increased
systemic complement activation in nAMD [18, 19]. The
systemic levels of C3a, C4a and C5a in different types of
nAMD (e.g. CNV, RAP, PCV and fibrosis) or in different
anti-VEGF therapy responder groups have not been in-
vestigated before, and such studies are important as dif-
ferent immunomechanisms may be involved in different
types of nAMD. In this study we found that higher
plasma levels of C3a, C4a and C5a are associated with
subretinal fibrosis and with CNV rather than RAP and
PCV and that C3a was significantly increased in patients
partially responding to anti-VEGF therapy.
How the complement system is activated in nAMD
patients and how this may contribute to the develop-
ment of nAMD is currently not well understood. Circu-
lating complement fragments such as C3a and C5a may
be recruited to the macula in AMD. Complement depos-
ition (e.g., C3a, C5a, C5b-9) has been detected in RPE,
Bruch’s membrane and choroid of AMD eyes [27]. Stud-
ies conducted in patient samples as well as in animal
models of laser-induced CNV have shown that comple-
ment activation may contribute to CNV development at
multiple levels. The membrane attack complex (MAC),
the final product of complement activation, may directly
induce CNV. C3-deficient mice are unable to form
MAC and do not develop CNV after laser photo-
coagulation. In the same study, CNV was suppressed
by inhibition of MAC formation through blockage of
C3 or C6 [28]. In addition, MAC can upregulate pro-
angiogenic factors such as VEGF, TGF-β2, and β-FGF
in retinal cells [28, 29]. Furthermore, the expression
of MAC is increased in choriocapillaris of the aging
macula and the expression is further enhanced in pa-
tients with AMD [30].
Anaphylatoxins were also shown to be involved in ex-
perimental CNV. C3a and C5a were increased in the
RPE/choroid after laser injury and blockage of C3a or
C5a resulted in reduced CNV formation. CNV was re-
duced in mice deficient in C3a or C5a receptors or in
mice treated with C3a or C5a receptor antagonist [14].
C3a and C5a were among the complement fragments
detected in the RPE of nAMD patients and both can in-
duce the expression of VEGF [14].
Systemic complement activation may also be in-
volved in the activation of choroidal endothelial cells.
C5a receptor was shown to be expressed in the endo-
thelium of human choriocapillaris and treatment of
human choroidal endothelial cells with C5a resulted
in increased expression of ICAM-1, an intercellular
adhesion molecule involved in leukocyte trafficking
[31]. Furthermore, anaphylatoxins have been shown to
be potent inflammatory mediators. Stimulation of hu-
man umbilical vein endothelial cells with C3a or C5a
resulted in upregulation of pro-inflammatory cytokine
production (e.g. IL-8 and IL-1β) [32]. C5a has been
shown to promote IL-22 and IL-17 expression from
human T-cells and both cytokines were shown to be
increased in the serum of AMD patients [33]. In
monocytes, C5a stimulation was shown to enhance
LPS-induced production of IL-6 and TNFα [34]. Sys-
temic complement activation may pre-condition leu-
kocytes to a pro-inflammatory phenotype and may
contribute to the local inflammatory responses in
nAMD when recruited to the aging macula.
The role of C4a in nAMD development remains
poorly elucidated [35] and deficiency of C4 did not
affect CNV formation following laser photocoagula-
tion in mice [36]. Nevertheless, in the present study
we detected elevated plasma levels of C4a in nAMD
patients, particularly in patients with CNV and in pa-
tients with subretinal fibrosis. Further studies are neces-
sary to investigate the role of C4a in the pathogenesis
of nAMD.
Table 5 Univariate analysis of C3a, C4a and C5a plasma levels in nAMD patients not responding, partially responding and
completely responding to anti-VEGF Ab therapy
Variables
(ng/ml)
Controls
(mean ± SD)
Non responders
(mean ± SD)
Partial responders
(mean ± SD)
Complete responders
(mean ± SD)
P value
n = 43 n = 4 n = 48 n = 44 Partial vs complete
respondersa
C3a 11.95 ± 3.30 13.97 ± 3.94 15.61 ± 5.18 13.67 ± 3.45 0.041
C4a 68.91 ± 33.23 79.97 ± 75.52 120.85 ± 98.30 97.57 ± 64.80 0.147
C5a 8.34 ± 2.05 8.62 ± 2.47 9.31 ± 2.72 9.63 ± 2.80 0.654
aIndependent samples t-test
Bold P < 0.05
SD standard deviation
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Subretinal fibrosis is a common finding in patients
with late stage nAMD leading to considerable impair-
ment of visual function although the underlying mecha-
nisms remain poorly defined [1]. In this study we report
significantly elevated plasma levels of C3a, C4a and C5a
in patients with subretinal fibrosis. Systemic alterations
in the complement system have previously been linked
to subretinal fibrosis in nAMD. Singh et al. found re-
duced expression of complement regulatory protein
CD46, which inhibits the production of C5a, on periph-
eral lymphocytes in nAMD patients with subretinal fi-
brosis [21]. C5a has been implicated in the development
of fibrosis in a mouse model of chronic pancreatitis,
where loss of C5 or injection of a C5a-receptor antagon-
ist significantly reduced the level of pancreatic fibrosis
[37]. Our results suggest uncontrolled complement acti-
vation and the formation of anaphylatoxins such as C3a,
C4a and C5a may contribute to the development of sub-
retinal fibrosis in nAMD and further studies are neces-
sary to understand the detailed mechanisms.
We observed increased plasma C3a levels in patients
partially responding to the anti-VEGF therapy when
compared to patients completely responding to the ther-
apy, suggesting C3a plasma level may be a biomarker in
predicting outcomes to treatment. Biological plausibility
for such an association exists in that C3a can induce the
expression of other pro-angiogenic factors including IL-
8 [38] which may explain why patients with increased
levels of C3a respond less well to the anti-VEGF treat-
ment. Furthermore, a SNP in the C3 gene has previously
been linked to reduced central retinal thickness follow-
ing anti-VEGF treatment [39], although subsequent
studies have failed to replicate these findings [40]. Poly-
morphisms of complement factor H, C2 as well as inter-
leukins IL-6 and IL-10 or VEGF genes are known to be
linked to nAMD risk and may affect the pathogenesis of
the disease [41]. These additional factors might also con-
tribute to the responsiveness to anti-VEGF therapy [41].
Why C3a but not C4a and C5a is associated with re-
sponsiveness to anti-VEGF therapy is not known. The
complement system can be activated through at least
three pathways i.e., the CP, AP, and MBL pathway. C3a
is generated when any of the pathways is activated,
whereas the generation of C4a is restricted to the CP or
MBL pathway and C5a to the terminal pathway. In
addition, a recent study has shown that C3 can be
cleaved into C3a and C3b intracellularly by cathepsin L
(i.e., independently of C3 convertase) [42]. Therefore,
changes in plasma levels of C3a, C4a and C5a may not
follow the same pattern. The serum levels of C3a were
similar in complete and non-responders, although only 4
patients were recruited to the non-responder group.
Nevertheless we contend that confirming our results in
a larger patient cohort and exploring the temporal
associations between plasma levels of C3a and morpho-
logical changes after anti-VEGF therapy are likely to help
elucidate the mechanisms of treatment responsiveness
to these agents.
In this study, we also found significantly increased
plasma levels of C3a, C4a and C5a in patients with
CNV, but not RAP or PCV when compared to controls,
suggesting that systemic complement activation may
play a bigger role in CNV than in RAP or PCV. How-
ever, the results must be interpreted with caution as
there were small numbers of participants in the RAP
and PCV group (n = 17 and 14 respectively). Further
studies using larger patient samples are necessary to
confirm the results.
The strengths of the present study include independ-
ent grading of CNV type, fibrosis and anti-VEGF re-
sponsiveness, and systematic and extensive exploration
of complement changes in different types of nAMD as
well as in patients partially or completely responding to
anti-VEGF treatment.
There are a number of limitations in the current study.
Firstly, the number of controls enrolled in this study is
relatively small and some of the analyses involved small
groups of patients (i.e. patients with RAP n = 17, patients
with PCV n = 14) with the attendant consequences of
drawing conclusions based on small samples. Secondly,
all participates were recruited from one location and the
data only represent results from Northern Ireland popu-
lation. Replication of the study findings in other loca-
tions and with much improved bigger numbers is
necessary to confirm our results. Thirdly, there was a
significant difference in age between nAMD patients
and controls. Furthermore, patients were recruited at
different times following diagnosis of nAMD. Conse-
quently, some patients enrolled at an early stage of
nAMD and classified as having no fibrosis, might still
develop fibrosis during the course of the disease. Pa-
tients enrolled in this study were receiving anti-VEGF
treatment prior to enrolment which may have altered
systemic complement levels although there was no cor-
relation with the number of anti-VEGF injections re-
ceived and the levels of C3a, C4a or C5a. Furthermore
the drug in use in our study site was ranibizumab which
is cleared more rapidly from the systemic circulation
and has the least effect on serum VEGF levels when
compared to other anti VEGF agents [43]. Finally, the
change of C3a and C5a in the whole study, while statisti-
cally significant, was small and the clinical and biological
relevance of such a small difference warrants further
investigations.
Conclusions
In this study, we have demonstrated systemic comple-
ment activation in nAMD, particularly in patients with
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CNV or with subretinal fibrosis, and we have shown
that higher plasma C3a levels are related to reduced
responsiveness to anti-VEGF treatment. Our observa-
tions may have important implications in future man-
agement of nAMD. Complement inhibitors are
currently in clinical trials for AMD [23, 24], and the
identification of suitable patients is important for the
success of this type of immune therapy. Our results
provide evidence that nAMD patients with CNV and
with subretinal fibrosis may benefit more from the
complement inhibitor therapy compared to other sub-
groups of nAMD patients. Complement inhibitors
may also be a supplement therapy for patients who
partially respond to VEGF inhibitors.
Methods
Study participants
The study protocol was approved by the Research
Ethics Committee of Queen’s University Belfast and
procedures were performed in accordance with the
tenets of the Declaration of Helsinki on research into
human volunteers. Participants were recruited from
the macular disease clinics in Belfast (Belfast Health
and Social Care Trust, UK) with written informed
consent obtained from every participant. Spouses,
relatives or friends who accompanied patients and
who were confirmed to be without retinal disease
(fundus photography and optical coherence tomog-
raphy (OCT)) were recruited as controls. All partici-
pants were older than 50 years of age and structured
questionnaires were used to ascertain a history of
medical conditions, current medication, family history
of AMD, smoking habits (current, ex-smoker, never
smoker) and body mass index (BMI). Participants
with systemic inflammatory or autoimmune disorders
(e.g. patients with active rheumatoid arthritis or
active chronic bronchitis), participants undergoing
steroid therapy or chemotherapy were excluded from
the study.
The diagnosis of nAMD was by clinical examination
and confirmed by multimodal imaging consisting of fun-
dus photography, autofluorescence, optical coherence
tomography, fluorescein angiography and Indocyanine
green angiography. Participants were further subcate-
gorised into CNV, RAP and PCV. Responsiveness to
treatment was defined based on the participant achiev-
ing a fluid free macula at any stage during follow up.
Participants were classified into the following 3 categor-
ies: Complete responder: Resolution of leakage at any
point in time during follow up; Partial responder: Exhi-
biting dependence on VEGF inhibitors but a fluid free
macula never achieved; Non responder: No morpho-
logical improvement or worsening.
Sample collection
In this study most of the participants were receiving
anti-VEGF therapy prior to enrolment. The number
of anti-VEGF (ranibizumab, trade name Lucentis,
Genentech, San Francisco, CA) injections received by
each patient prior to blood collection was ascertained
from the medical records. Peripheral blood samples
were drawn in tubes containing ethylenediaminetetra-
acetic acid (EDTA) as an anticoagulant between 9:00
and 12:00 am and processed within three hours. The
plasma was separated from the whole blood by centri-
fugation for 10 min at 300 g. The plasma fraction was
collected and centrifuged again for 10 min at 2000 g
to remove any residual cells and platelets before it
was aliquoted and stored at −80 °C until analysis.
Cytometric bead array
Complement fragments C3a, C4a and C5a were mea-
sured in the plasma by Cytometric Bead Array using
a Human Anaphylatoxin Kit (BD Biosciences, Oxford,
UK) according to the manufacturer’s instructions. In
order to avoid spontaneous complement activation,
plasma samples were thawed rapidly at 37 °C until
just thawed and immediately transferred to ice.
Plasma samples were diluted 1:20 with assay diluent
prior to analysis.
Briefly, capture beads were mixed and incubated with
diluted plasma samples and standards for 2 h at room
temperature. After the incubation, samples were
washed with wash buffer and incubated with anaphyla-
toxin PE detection reagent for 1 h at room temperature
protected from light. After another washing step, sam-
ples were resuspended in wash buffer and fluorescence
intensities were measured by flow cytometry (FACS
CANTO II; BD Biosciences). Concentrations were cal-
culated using the FCAP Array software version 3.0 (BD
Biosciences, Oxford, UK).
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences, Windows version 21
(SPSS Inc, Armonk, NY). Categorical demographic
and clinical data were compared using Pearson’s chi-
square test. The distribution of continuous variables
was assessed for normality using the Kolmogorov-
Smirnov test and logarithmic transformation was per-
formed if necessary to achieve normal distribution.
Normally distributed continuous samples were then
compared using the Independent samples t-test or
one-way ANOVA. Age was not normally distributed
and the difference between controls and nAMD pa-
tients was analysed using the Mann–Whitney U test.
For the associations that were significant in the uni-
variate analysis, multinomial logistic regression was
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performed to adjust for age and gender. All variables
were also tested for association with family history of
AMD, history of cardiovascular disease, history of
hypertension, history of diabetes, smoking habits,
BMI, taking of cardiovascular medication, vitamins
and low-dose aspirin using the Independent samples
t-test, one-way ANOVA or Pearson’s correlation. If
significant associations were identified, adjustments
were made in the multinomial logistic regression ana-
lysis. Pearson’s correlation was used to assess the cor-
relation between the number of anti-VEGF injections
a patient had received prior to blood collection and
the concentration of complement components. Data
were presented as mean ± standard deviation (SD) calcu-
lated from untransformed variables even if the statis-
tical analysis was performed on transformed variables.
P values <0.05 were considered statistically significant.
Additional file
Additional file 1: Figure S1. The relationship between the number of
anti-VEGF injections and the concentration of complement fragments in
the plasma. No correlation was observed between the number of
intravitreal anti-VEGF injections and the plasma levels of C3a, C4a and C5a.
(PDF 118 kb)
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